Core Viewpoint - ST Bio (000504) forecasts a net profit of 28.5 million to 32.5 million yuan for the year 2025, indicating a positive outlook for the company's financial performance [1] Financial Performance Summary - The expected net profit for 2025 is between 28.5 million yuan and 32.5 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be between 8.5 million yuan and 12.5 million yuan [1]

*ST生物（000504）1月22日晚间公告称，终止筹划重大资产重组。 公告显示，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股权收购意向协议的提示性公 告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限合伙）、长沙市履方医药信 息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司51%股权。本次筹划重组事项 尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公司与交易各方签署了《股权收 购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，本次重大资产重组的终止，不会对公司现有生产经营活动、财务状况产生重大不利影响。 目前公司生产经营秩序正常，本次交易的终止不存在损害公司及全体股东尤其是中小股东利益的情形。 *ST生物22日发布的2025年年度业绩预告称，预计2025年营业收入3.8 ...

Shareholder Reduction Plans - Junchen Technology's shareholder Junchen Partnership plans to reduce its stake by no more than 2.94% [1] - Wuchan Jinlun's shareholder Jinlun Holdings intends to reduce its stake by no more than 3% [1] - Haiguang Information's major shareholder Blue Ocean Lightboat Partnership plans to reduce its stake by no more than 0.50% [1] - Boyun New Materials' shareholder Gao Chuang Investment plans to reduce its stake by no more than 1% [1] - Green Alliance Technology's shareholder Cyber Security Fund plans to reduce its stake by no more than 3% [1] - Te Fa Service's shareholder Yinkun Company plans to reduce its stake by no more than 3% [1] - Mengcao Ecology's actual controller Wang Zhaoming plans to reduce his stake by no more than 2.3311% [1] - Huatu Shanding's shareholder Che Lu plans to reduce his stake by no more than 3% [1] - Heshun Electric's shareholder Shen Xin plans to reduce his stake by no more than 2.5% [1] - Ruihua Tai's shareholder Ju Yao Kun plans to reduce his stake by no more than 540,000 shares [1] - Luokai Co., Ltd.'s shareholders Luohui Investment, Luoteng Investment, and Luosheng Investment plan to reduce their total stake by 378,030 shares [1] - Zhongke Feice's shareholder Guotou Chuangye Fund plans to reduce its stake by 234,870 shares [1] - Tuo Jing Technology's shareholder National Integrated Circuit Fund has already reduced its stake by 297,760 shares [1] Other Significant Developments - *ST Biology has terminated its major asset restructuring plan [1] - *ST Biology's stock may face delisting [1]

Core Viewpoint - *ST Bio (000504) expects significant revenue growth in 2025, projecting operating income between 385 million to 425 million yuan, compared to approximately 130 million yuan in the previous year, indicating a substantial year-on-year increase [2][5]. Financial Performance - The company anticipates a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan, and net profit after deducting non-recurring gains and losses projected at 8.5 million to 12.5 million yuan, all indicating a turnaround from previous losses [2][5]. - Basic earnings per share are forecasted to be between 0.025 yuan and 0.037 yuan, a recovery from a loss of 0.06 yuan per share in the previous year [5]. Revenue Drivers - The revenue increase is attributed to the acquisition of Loudi Jinhong New Materials Co., which enhanced the company's recycling business, particularly in the areas of waste battery and scrap steel recycling [5][6]. - The company has also expanded sales of related products in its main business, including beauty and health products linked to its biopharmaceutical operations, contributing to revenue and profit growth [5][6]. Cost Management - In 2025, *ST Bio implemented cost reduction and efficiency improvement measures, including organizational restructuring, personnel optimization, and expense control, which enhanced profitability [6]. Regulatory Context - 2025 is a critical year for *ST Bio to avoid delisting, as the company faced a risk warning due to negative profits and revenue below 300 million yuan in 2024 [7]. - The company can apply to lift the delisting risk warning if it meets specific financial criteria in the subsequent annual report [7]. Asset Restructuring - Concurrently, *ST Bio announced the termination of a major asset restructuring plan aimed at acquiring a 51% stake in Hunan Huize Biopharmaceutical Technology Co., a professional CRO company [11][12].

Group 1 - Honghe Technology's main product, electronic-grade glass fiber cloth, is one of the basic materials for PCB [1] - *ST Bio has terminated the planning of a major asset restructuring [1] - Dongpeng Beverage plans to invest 1.1 billion yuan in the "Dongpeng Beverage Chengdu Production Base Project" [1] - AudioFly Storage has won the equipment procurement project for Jingdezhen Art Vocational University [1] - ShenNan Electric A expects a net profit growth of 584.66% to 721.59% year-on-year in 2025 [1] - Shuihui Supermarket plans to sell 28.095% of its stake in Yunjin Technology to Paihui Technology [1] - Hengyi Petrochemical intends to repurchase shares worth 500 million to 1 billion yuan [1] - Mongolian Grass Ecology's actual controller Wang Zhaoming plans to reduce his stake by no more than 2.3311% [1] - Jiangsu Yinglian Recycled Fluid has signed a "Joint Laboratory Strategic Agreement" with LG Chem [1] - Lizhong Group has received a fixed-point notification for an aluminum alloy wheel project from a client [1] Group 2 - Hengyi Petrochemical plans to repurchase shares worth 500 million to 1 billion yuan [2] - Yinglian shares' subsidiary has signed a "Joint Laboratory Strategic Agreement" with LG Chem [2] - Yunyi Electric plans to repurchase shares worth 100 million to 150 million yuan [2] - Xiduan Pharmaceutical intends to repurchase shares worth 25 million to 50 million yuan [2] - Junchen Technology's controlling partner plans to reduce its stake by no more than 2.94% [2] - Green Alliance Technology's cybersecurity fund plans to reduce its stake by no more than 3% [2] - Mongolian Grass Ecology's actual controller Wang Zhaoming plans to reduce his stake by no more than 2.3311% [2] - Yunyi Electric's chairman and general manager Fu Hongling plans to increase his stake by 30 million to 60 million yuan [2] - Lizhong Group has received a fixed-point notification for an aluminum alloy wheel project from a client [2]

突发公告，终止筹划重大资产重组。 *ST生物（000504）1月22日晚间公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股 权收购意向协议的提示性公告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限 合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司 51%股权。本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公 司与交易各方签署了《股权收购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，终止本次交易系公司与相关各方经充分沟通、审慎分析及友好协商后作出的决定，各方就 本次交易终止无需承担任何违约责任。本次重大资产重组的终止，不会对公司现有生产经营活动、财务 状况产生重大不利影响。目前公司生产经营秩序正常，本次交易的终止不存在损害公司及 ...

突发公告，终止筹划重大资产重组。 *ST生物（000504）1月22日晚间公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股 权收购意向协议的提示性公告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限 合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司 51%股权。本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公 司与交易各方签署了《股权收购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，终止本次交易系公司与相关各方经充分沟通、审慎分析及友好协商后作出的决定，各方就 本次交易终止无需承担任何违约责任。本次重大资产重组的终止，不会对公司现有生产经营活动、财务 状况产生重大不利影响。目前公司生产经营秩序正常，本次交易的终止不存在损害公司及 ...

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ *ST生物（维权）（000504）重大资产重组告终。 *ST生物1月22日公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股权收购意向协议 的提示性公告》，本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议。 时隔5个月后，重组失败。2026年1月22日公司与交易各方签署了《股权收购意向协议之终止协议》，终 止筹划收购湖南慧泽生物医药科技有限公司（简称"慧泽医药"）51%股权的重大资产重组事项。 *ST生物表示，收购慧泽医药，一方面有利于上市公司生物医药板块业务发展延伸，从而进一步增强上 市公司主营业务的盈利能力，提升上市公司抗风险能力；另一方面细胞临床转化研究和药物研发及临床 评价业务上具有较强的关联性，通过资产整合，将有利于提升公司经营效率，具有较强的协同效应。 事实上，筹划重组前，*ST生物于2025年4月30日起被实施退市风险警示，公司股票简称由"南华生 物"变更为"*ST生物"。 就重组失败原因，*ST生物表示，交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能 最终达成一致。为切实维护 ...

*ST生物（000504）(000504.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利润2850 万元–3250万元，扭亏为盈;扣除非经常性损益后的净利润850万元–1250万元。 ...